Biogen Inc

Biogen has initiated a Phase 3 pediatric study of omaveloxolone, a treatment for Friedreich ataxia, in a move that offers hope to families affected by the rare neurodegenerative disorder.

Biogen has completed its Phase 3 trial for Dapirolizumab Pegol, meeting its primary objective, with its stock price currently at $131.04.

Biogen has made a major breakthrough in its phase 3 trial of Dapirolizumab Pegol for Systemic Lupus Erythematosus, a significant step towards treating the debilitating autoimmune disease.

Biogen has announced the successful completion of a Phase 3 trial for a treatment for Systemic Lupus Erythematosus, marking a significant step forward in the company’s research efforts.

Biogen and UCB’s dapirolizumab pegol has shown significant promise in treating systemic lupus erythematosus (SLE), with positive results from a Phase 3 trial indicating a potential game-changing treatment for the condition.

Biogen Inc. has announced positive results from a Phase 3 trial of dapirolizumab pegol, a potential treatment for systemic lupus erythematosus (SLE), showing significant clinical improvements in disease activity and fatigue symptoms.

Biogen’s strategic partnership with City Therapeutics is a game-changer, providing access to cutting-edge RNAi technology and new revenue streams, and propelling the company into a new era of growth and profitability.

Biogen and City Therapeutics have formed a strategic partnership to develop innovative RNAi therapies, combining their expertise to create game-changing treatments for a wide range of diseases.

Biogen and City Therapeutics have formed a groundbreaking partnership to develop novel RNAi therapies for central nervous system diseases, leveraging cutting-edge technologies and expertise to potentially transform patient outcomes.

Biogen Inc’s stock price plummeted 4.93 US dollars in a single day, a victim of market volatility ahead of the Federal Reserve’s interest rate decision.